Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy <i>In Vitro</i> and <i>In Vivo</i>

<table>Dose-related cytotoxicity following 72 h exposured to sorafenib. The IC50 of sorafenib was indicated by the intersection of the plotted line. Sorafenib was 31 <i>μ</i>M.</table>

Gastroenterology Research and Practice

fig2

Figure 2

Figure 2: Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy <i>In Vitro</i> and <i>In Vivo</i> 

Gastroenterology Research and Practice

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo

Figure 2